ClinicalTrials.Veeva
Menu

Find clinical trials for Triple Negative Breast Cancer in Nashville, TN

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Breast Cancer
Cancer
Carcinoma
Squamous Cell Carcinoma of Head and Neck
Endometrial Cancer
Non-Small-Cell Lung Carcinoma
Ovarian Cancer

Triple Negative Breast Cancer trials near Nashville, TN, USA:

Carboplatin With or Without Atezolizumab in Treating Patients With Stage IV Triple Negative Breast Cancer

This randomized phase II trial studies how well carboplatin with or without atezolizumab works in treating patients with stage IV triple negative...

Active, not recruiting
HER2 Negative
Triple Negative Breast Cancer
Other: Laboratory Biomarker
Other: Quality-of-Life Assessment

Phase 2

Vanderbilt University Medical Center
Vanderbilt University Medical Center

Nashville, Tennessee, United States and 5 other locations

The purpose of this study is to determine if a combination of two drugs ipatasertib and atezolizumab works as a treatment for residual cancer...

Active, not recruiting
Breast Cancer
Circulating Tumor DNA
Drug: Atezolizumab
Drug: Sacituzumab govitecan

Phase 2

Dana-Farber Cancer Institute
Dana-Farber Cancer Institute

Nashville, Tennessee, United States and 8 other locations

oral immuno-oncology product candidate targeting immune-suppressive tumor-associated myeloid cells through selective inhibition of phosphoin ...

Active, not recruiting
Breast Cancer
Renal Cell Carcinoma
Drug: nab-paclitaxel
Drug: Bevacizumab

Phase 2

Infinity Pharmaceuticals
Infinity Pharmaceuticals

Nashville, Tennessee, United States and 23 other locations

avelumab with sacituzumab govitecan works in treating patients with triple negative breast cancer that is stage I...

Enrolling
Stage IIIA Breast Cancer
Recurrent Breast Carcinoma
Biological: Utomilumab
Biological: Anti-OX40 Antibody PF-04518600

Phase 2

Hope Rugo, MD

Nashville, Tennessee, United States and 11 other locations

This study is one single group of participants with non-small cell lung cancer (NSCLC) who have not been cured by other treatments. It is th...

Enrolling
Hormone Receptor Positive Breast Cancer
Non-small Cell Lung Cancer
Drug: Steroid Containing Mouthwash
Other: Non-Steroid Containing Mouthwash

Phase 1

Daiichi Sankyo
Daiichi Sankyo

Nashville, Tennessee, United States and 17 other locations

This is a Phase III, randomised, open-label, 2 arm, multicentre, international study assessing the efficacy and safety of Dato-DXd compared with ICC...

Active, not recruiting
Breast Cancer
Drug: Paclitaxel
Drug: Eribulin mesylate

Phase 3

AstraZeneca
AstraZeneca

Nashville, Tennessee, United States and 228 other locations

the RP2D. The RP2D will be administered to 3 cohorts of patients in the Dose Expansion Phase.* Cohort A: Advanced or Metastatic Triple Negative...

Active, not recruiting
Endometrial Cancer
Solid Tumor, Unspecified, Adult
Drug: Fruquintinib
Drug: Tislelizumab

Phase 1, Phase 2

HUTCHMED
HUTCHMED

Nashville, Tennessee, United States and 15 other locations

previously untreated, locally advanced, inoperable or metastatic triple-negative breast cancer whose tumors...

Enrolling
Triple Negative Breast Cancer
PD-L1 Negative
Drug: Sacituzumab Govitecan-hziy
Drug: Paclitaxel

Phase 3

Gilead Sciences
Gilead Sciences

Nashville, Tennessee, United States and 516 other locations

AGX101 is an antibody-drug conjugate (ADC) therapy for tumor-forming cancers. The purpose of this study is to learn about AGX101 ef...

Enrolling
Advanced Cancer
Pancreas Cancer
Drug: AGX101

Phase 1

Angiex, Inc.

Nashville, Tennessee, United States and 1 other location

CAR T-cell therapy, in patients with ROR1+ relapsed or refractory triple negative breast cancer (TNBC), non-small...

Active, not recruiting
Relapsed Cancer
TNBC - Triple-Negative Breast Cancer
Biological: LYL797

Phase 1

Lyell Immunopharma

Nashville, Tennessee, United States and 17 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems